Mayne Pharma Group Limited
MAYNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.05 | 0.13 | -0.00 |
| FCF Yield | 1.25% | -9.77% | -82.89% | -153.11% |
| EV / EBITDA | 9.46 | -3.79 | -1.51 | -7.24 |
| Quality | ||||
| ROIC | -3.22% | -14.27% | -23.06% | -18.88% |
| Gross Margin | 60.59% | 56.30% | 14.62% | 108.27% |
| Cash Conversion Ratio | -0.19 | 0.09 | 0.14 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | 30.51% | 35.18% | -22.88% | -29.92% |
| Free Cash Flow Growth | 114.36% | 86.23% | -822.72% | -228.49% |
| Safety | ||||
| Net Debt / EBITDA | -0.44 | 0.45 | 0.31 | -6.84 |
| Interest Coverage | -0.68 | -4.03 | -17.83 | -4.22 |
| Efficiency | ||||
| Inventory Turnover | 3.18 | 2.27 | 1.90 | 2.33 |
| Cash Conversion Cycle | 193.33 | 297.37 | 505.46 | 688.24 |